Study of Subcutaneous Trastuzumab-Pertuzumab Phesgo Before Surgery for Early Stage HER2-Positive Breast Cancer in Algerian Women

What this Trial Is About

Researchers are evaluating the effectiveness and tolerability of the subcutaneous combination of trastuzumab and pertuzumab Phesgo as neoadjuvant treatment in Algerian women with early-stage, HER2-positive breast cancer. This observational study will include about 70 adult women diagnosed with non-metastatic HER2-positive breast cancer and aims to assess how well this treatment works before surgery. Participants will receive Phesgo alongside standard chemotherapy for approximately 18 weeks before undergoing surgery. The study takes place in three oncology centers across Algeria and focuses on real-world application to see if this treatment can simplify delivery, reduce hospital burden, and improve access to care in areas with limited healthcare resources. During the study, researchers will monitor outcomes including the rate of complete destruction of invasive cancer in the breast and nearby lymph nodes at surgery, the rate of breast-conserving surgery, incidence of side effects, patient satisfaction with treatment, and factors predicting treatment response. Follow-up assessments will occur from treatment start through surgery and shortly after, with safety monitored until 30 days after the last dose.

Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer